A phase 1 study of the pharmacokinetics of nucleoside analog trifluridine and thymidine phosphorylase inhibitor tipiracil (components of TAS-102) vs trifluridine alone

Background Trifluridine, a thymidine-based chemotherapeutic, has limited bioavailability after clinical administration as it is rapidly degraded via thymidine phosphorylase. An oral combination tablet combines trifluridine with a potent thymidine phosphorylase inhibitor, tipiracil hydrochloride. Thi...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Invest New Drugs
Egile Nagusiak: Cleary, James M., Rosen, Lee S., Yoshida, Kenichiro, Rasco, Drew, Shapiro, Geoffrey I., Sun, Weijing
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Springer US 2017
Gaiak:
Phase I Studies
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5352756/
https://ncbi.nlm.nih.gov/pubmed/28111727
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-016-0409-9
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak